Clinical Trials on AMI in Australia

Total 66 results

Eilean Therapeutics

Recruiting

Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers

AML

Australia
University of Applied Sciences Upper Austria
Krankenhaus der Barmherzigen Schwestern Ried

Unknown

The Effects of Regular Eye-training With a Mobile Device on Adult Patients With AMD (ETAMD)

AMD

Austria
Biotronik AG

Completed

PROGRESS-AMS 1.0 Clinical Long Term Follow-Up

Long Term Safety of the AMS 1.0

Switzerland, Germany, Australia, Belgium, Netherlands
Klinikum Floridsdorf
Medical University of Vienna; Klinik Favoriten; Salzkammergut Klinikum Vöcklabruck

Completed

BMI and Lymph Node Count in Colorectal Cancer

The Aim of This Study is to Determine the Influence of BMI and Lymph Node Status on OS in CRC Patients in the Long Term

Austria
Renibus Therapeutics, Inc.

Completed

Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing CABG and/or Cardiac Valve Surgery (START)

AKI

United States, Australia, Canada
CSL Limited

Completed

Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)

Australia
Peter MacCallum Cancer Centre, Australia
GlaxoSmithKline; Celgene Corporation

Completed

A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia (Aza-E)

Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukaemia (AML)

Australia
Eilean Therapeutics

Not yet recruiting

Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia

AML With Gene Mutations

Australia
Center for Eye Research Australia

Recruiting

Project AMD: Comprehensive Characterisation of Age-Related Macular Degeneration and Its Progression (Project AMD)

Age-related Macular Degeneration | Geographic Atrophy | Age Related Macular Degeneration | AMD

Australia
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS) | Acute Myeloid Leukaemia (AML)

France, Australia
Maxinovel Pty., Ltd.

Recruiting

MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia (AML)

Australia
University of Birmingham

Completed

A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) (PARC)

Cancer | Pediatric ALL | Pediatric Solid Tumor | Pediatric AML

United Kingdom, Australia, Netherlands
Eisai Inc.

Terminated

Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

Pediatric Acute Myelogenous Leukemia (AML)

United States, Canada, Australia
GWT-TUD GmbH

Recruiting

Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML (PALOMA)

AML | MDS

Germany, Austria
Novartis Pharmaceuticals

Terminated

Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia

AML | cKIT-positive Solid Tumors

Belgium, Spain, Australia, Netherlands
Medical University of Vienna
Ferring Arzneimittel GmbH

Recruiting

Hormones in Hypogonadotropic Hypogonadism

Hypogonadism, Hypogonadotropic | AMH | Follicle Cyst

Austria
Ascentage Pharma Group Inc.

Recruiting

A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)

AML, Adult

Australia, United States
Novartis Pharmaceuticals

Completed

Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre) (FLUID)

Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD

Australia
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS) | Acute Myeloid Leukaemia (AML)

United States, Australia, France, Spain
Astellas Pharma Global Development, Inc.

No longer available

Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Acute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) Mutations

Australia, Italy, United Kingdom
Datascope Corp.
Duke University; Flinders Medical Centre

Completed

Counterpulsation Reduces Infarct Size Pre-PCI for AMI (CRISP-AMI)

Acute Myocardial Infarction (AMI)

United States, Germany, Australia, Ireland, India, United Kingdom, Belgium, France, Italy, Netherlands
Oraya Therapeutics, Inc.

Completed

INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD (INTREPID)

Eye Diseases | Age-Related Macular Degeneration | Macular Degeneration | Retinal Diseases | AMD | Wet AMD | Wet Age-Related Macular Degeneration

United Kingdom, Czech Republic, Austria, Germany, Italy
Medicure

Recruiting

Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency (MEND-PNPO)

Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency

United States, Australia
Institut de Recherches Internationales Servier

Active, not recruiting

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE)

Leukemia, Myeloid, Acute | Untreated AML | Newly Diagnosed Acute Myeloid Leukemia (AML) | AML Arising From Myelodysplastic Syndrome (MDS)

Spain, United States, France, Korea, Republic of, Taiwan, Australia, Canada, Germany, China, Italy, Austria, Czechia, Poland, Japan, United Kingdom, Russian Federation, Netherlands, Brazil, Israel, Mexico
AbbVie
Genentech, Inc.

Completed

A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia

AML | Acute Myelogenous Leukemia

United States, Australia, Germany, Italy
Celgene
AbbVie

Completed

A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML) (OMNIVERSE)

Leukemia, Myeloid, Acute

United States, Australia
Array BioPharma

Completed

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

AML | Advanced and Selected Solid Tumors | High Risk and Very High Risk MDS

United States, Australia, Italy, Spain, France, Switzerland, United Kingdom
Hoffmann-La Roche

Terminated

A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) (MIRROS)

Leukemia, Myeloid, Acute

Italy, Korea, Republic of, Belgium, Australia, United States, Canada, United Kingdom, Spain, Netherlands, France, Germany, New Zealand, Israel, Norway, Russian Federation, Switzerland, Austria, Finland, Panama
Daiichi Sankyo, Inc.

Completed

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

AML

United States, Korea, Republic of, Taiwan, United Kingdom, France, Australia, Spain, Italy, Canada, Singapore, Germany, Netherlands, Hong Kong, Belgium, Croatia, Czechia, Hungary, Poland, Serbia
Kartos Therapeutics, Inc.

Terminated

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

Relapsed or Refractory Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)

United States, Spain, Korea, Republic of, Belgium, United Kingdom, Hungary, France, Germany, Israel, Australia, Italy, Poland
Amgen

Terminated

Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (20170528)

Relapsed/Refractory Acute Myeloid Leukemia (AML)

United States, Korea, Republic of, Australia, Japan, Germany, Canada
Novo Nordisk A/S
Duke Clinical Research Institute

Not yet recruiting

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack (ARTEMIS)

Cardiovascular Risk | Acute Myocardial Infarction (AMI)

Canada, China, United States, Germany, Spain, Korea, Republic of, Netherlands, Australia, Italy, Denmark, India, United Kingdom, Argentina, Turkey, Mexico, Malaysia, Czechia, Poland, Brazil, France, Japan, Bulgaria, Greece, Israel
AbbVie
Genentech, Inc.

Terminated

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia | Myelogenous Leukemia | Treatment Naive AML

United States, Australia, France, Germany
Servier Affaires Médicales

Recruiting

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

Acute Myeloid Leukemia (AML)

Netherlands, Italy, Austria, France
Novartis Pharmaceuticals

Completed

A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

AML and High Risk MDS

Germany, Italy, France, Netherlands, United States, Australia, Japan
Clavis Pharma

Completed

Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) (CLAVELA)

Acute Myeloid Leukemia (AML)

United States, Spain, France, Ireland, United Kingdom, Australia, Belgium, Canada, Germany, Italy, Norway, Poland, Romania
University Hospital, Basel, Switzerland

Recruiting

Emergency Department Triage of Patients With Acute Chest Pain Based on the ESC 0/1-hour Algorithm (PRESC1SE-MI) (PRESC1SE-MI)

NSTEMI - Non-ST Segment Elevation MI | Acute Chest Pain

United Kingdom, Switzerland, Spain, Korea, Republic of, United States, Australia, Austria, Finland, Greece, Italy, Romania
Hannover Medical School

Completed

Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML

Acute Myeloid Leukemia (AML)

Austria, Czechia, Germany
University of Ulm

Completed

Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine (azacitidine)

Acute Myeloid Leukemia (AML)

Germany, Austria
Bioeq GmbH

Completed

Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration (COLUMBUS-AMD)

Age-related Macular Degeneration (AMD)

France, Italy, Poland, Russian Federation, Spain, United Kingdom, Germany, Hungary, Ukraine, Austria, Czechia, Israel
Novartis Pharmaceuticals

Active, not recruiting

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome (MDS)

Spain, Singapore, Australia, Germany, Italy, Finland, United States
University of Ulm

Completed

Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

Germany, Austria
RobotDreams GmbH

Recruiting

AI Algorithms in Prediction of ACS Based on Leukocyte Properties

Angina Pectoris | Acute Coronary Syndrome | NSTEMI - Non-ST Segment Elevation MI | STEMI - ST Elevation Myocardial Infarction

Austria
University of Ulm

Completed

Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)

Acute Myeloid Leukemia (AML)

Germany, Austria
Astex Pharmaceuticals, Inc.

Completed

SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction

Leukemia, Myeloid, Acute

United States, Spain, Korea, Republic of, Taiwan, Australia, Canada, Denmark, Hungary, Japan, Finland, Italy, Serbia, Czechia, France, Germany, Sweden, Netherlands, Poland, Russian Federation, Austria, United Kingdom, Romania, Belgium, Bulgar...
AbbVie
Genentech, Inc.

Active, not recruiting

A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy (Viale-a)

Acute Myeloid Leukemia (AML)

United States, Australia, Austria, Belgium, Brazil, Canada, China, Croatia, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Norway, Poland, Portugal, Puerto Rico, Russian Federation, South... and more
AbbVie
Roche-Genentech

Active, not recruiting

A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)

Acute Myeloid Leukemia (AML)

United States, Australia, Canada, China, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Puerto Rico, Russian Federation, Spain, Taiwan, Turkey, United Kingdom
Antisoma Research

Unknown

Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study

Secondary Acute Myeloid Leukemia (Secondary AML, sAML)

Korea, Republic of, United States, Spain, United Kingdom, Australia, Austria, Taiwan, Israel, Italy, Belgium, Germany, France, Romania, Estonia, Canada, Ukraine, Ecuador, Hungary, Poland, Chile, Argentina, Czech Republic, Russian Federation
Novartis Pharmaceuticals

Completed

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

United States, Spain, Belgium, Germany, Japan, Taiwan, Turkey, Italy, Australia, Austria, Switzerland, Israel, Bulgaria, France, Norway, Brazil, Poland, Portugal, Czechia, Argentina
Gyroscope Therapeutics Limited
Novartis Pharmaceuticals

Enrolling by invitation

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study (ORACLE)

Age Related Macular Degeneration (AMD)

United States, Germany, Spain, France, Australia, United Kingdom

Clinical Trials on AMI in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations